Clinical Trial Update: Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating immunogenicity of dose-reduction strategies for the MVA-BN Monkeypox vaccine; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monkeypox

Drugs mentioned

• MVA-BN Monkeypox vaccine (Modified Vaccinia Ankara-Bavarian Nordic vaccine (MVA-BN))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Monkeypox | Phase 2 | Status: COMPLETED | Results posted: 2024-01-09